William Blair Reiterates “Outperform” Rating for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX)‘s stock had its “outperform” rating reaffirmed by research analysts at William Blair in a research note issued on Thursday,RTT News reports. William Blair also issued estimates for Hologic’s Q3 2025 earnings at $1.12 EPS, Q4 2025 earnings at $1.10 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.17 EPS and FY2026 earnings at $4.55 EPS.

Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. increased their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Royal Bank of Canada increased their price objective on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. UBS Group lifted their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Jefferies Financial Group started coverage on Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target for the company. Finally, BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Ten analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $85.77.

Hologic Stock Down 1.3 %

HOLX opened at $64.58 on Thursday. The firm’s 50 day simple moving average is $72.33 and its two-hundred day simple moving average is $77.76. The company has a market capitalization of $14.58 billion, a PE ratio of 19.39, a PEG ratio of 2.35 and a beta of 0.98. Hologic has a 1-year low of $63.88 and a 1-year high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. As a group, equities analysts forecast that Hologic will post 4.28 EPS for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.88% of the company’s stock.

Institutional Trading of Hologic

A number of large investors have recently modified their holdings of HOLX. Benson Investment Management Company Inc. bought a new stake in Hologic during the 4th quarter valued at $4,832,000. Clean Yield Group lifted its stake in Hologic by 18.9% in the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after acquiring an additional 7,266 shares during the period. GAMMA Investing LLC lifted its stake in Hologic by 17.9% in the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock worth $312,000 after acquiring an additional 582 shares during the period. Janus Henderson Group PLC increased its position in Hologic by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after purchasing an additional 800 shares during the period. Finally, Versor Investments LP bought a new stake in shares of Hologic in the 3rd quarter valued at about $1,677,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.